News

  • Topical Steroid Withdrawal

    The National Eczema Society (NES) has been receiving enquiries from patients worried about using topical corticosteroids (TCS) and of the risk of Topical Steroid Withdrawal. They have also seen more activity on social media by people campaigning for greater recognition of the risks of Topical Steroid Withdrawal, coupled with a rise in potentially confusing and inaccurate information available online.

    While remaining evidence-based, NES wanted to move to a position where they recognised and more openly acknowledged Topical Steroid Withdrawal, and people’s individual choice in deciding how they manage their eczema. This is a complex area and the research literature is limited.

    The NES has worked jointly with the British Association of Dermatologists to produce information for patients on this topic. This statement is available as a related document on this section of the NES website

  • Skin Deep - Improving the diversity of skin images online

    The BDNG proudly supports Skin Deep.

    Skin Deep is led by the international medical education team, Don’t Forget the Bubbles (DFTB) and the Royal London Hospital (RLH). The aim is to develop a free, open-access bank of high-quality photographs of medical conditions in a range of skin tones for use by both healthcare professionals and the public. The team behind Skin Deep hopes that with time, this will improve education and recognition of conditions in all skin tones, reducing inequalities and improving patient care by ensuring that all children receive a timely diagnosis regardless of their skin colour. Visit the website,  follow on Twitter and Instagram

  • Mobilising Knowledge - The Secondary Care Perspective Stakeholder Event

    Eczema Care Online (ECO) is an NHS-funded programme of research designed to improve self-management of eczema amongst patients and parents. This is a joint collaboration between the University of Southampton and the University of Nottingham.  

     

    As part of this research, they have been reviewing the published evidence about safety and effectiveness of topical corticosteroids for eczema. They have recently completed this research and would like to consult with key stakeholders about how findings can best be refined and disseminated to maximise their usefulness. 

    They would like to hear from BDNG members who would be interested in attending our stakeholder event,  ‘Mobilising Knowledge – the Secondary Care Perspective’ on Friday 12th March (12:30-2:00). This event will involve a small number of dermatologists and dermatology nurses. At the event they will share the latest information from ECO and consider how this information might best inform clinical practice. Click here for more information

    For more information about the ECO project please visit the website(Hyperlink  website to https://www.nottingham.ac.uk/eco/index.aspx)

  • Non-Melanoma Skin Cancer: Tackling the most common cancer in the time of Covid-19

    Sanofi Genzyme recently hosted a parliamentary roundtable looking at how to tackle NMSC in the time of Covid-19. This meeting brought together parliamentarians, healthcare professionals and patient support charities. Participants discussed the current challenges in NMSC care and explored the importance of prevention and awareness. Click here to read the report.

  • Eczema Unmasked

    LEO Pharma recognises the important role of working closely with patient advocacy groups to raise awareness of the varied and often significant challenges people face living with dermatological conditions and call for positive change. We are therefore extremely proud to have partnered with the National Eczema Society to commission the ‘Eczema Unmasked’ report, with insights from over 1,000 people affected by the condition.

    Eczema Unmasked raises awareness of the extensive and under-recognised impact eczema can have on all aspects of peoples’ lives including impact on people’s physical health, mental health, their quality of life, long-term life opportunities – highlighting the variation in healthcare provision and measures that must be taken to bridge these gaps in care.

    Based on these findings LEO Pharma and the National Eczema Society are calling for the voices of those living with eczema to be strengthened, the development of clinical guidelines and quality standards for adults and adolescents with eczema and lastly, improve access to appropriate care and services.

    Read the report

    Key findings

    Eczema can affect physical health: 96% of adults and 95% of children experienced itchy skin, many severely, and 67% of adults and 60% of children have had skin so sore that it bleeds.

    Eczema can affect mental health: Almost three quarters of adults (74%) stating it had negatively impacted their mental health and 2/3 (66%) of patients said they were lonely/socially isolated because of their eczema. Despite this, less than half had been offered access to emotional or psychological support to help them to manage this.

    Eczema can affect day to day life: 89% of adults said eczema significantly reduced their quality of life and 76% of parents said their child’s quality of life is significantly affected.

    Eczema can limit life opportunities: Nearly half of adult responders (49%) said eczema had affected their ability to do paid work.

    Accessing care and treatment can be challenging: Nearly a third (29%) of adults, and a third (33%) of parents say they have difficulty obtaining the emollients they need from the NHS, while over a quarter (28%) say the same about challenges accessing biologic treatment.

  • Research development needs of dermatology nurses

    The BDNG is collaborating with the UKDCTN to identify how we can best support the research development needs of the dermatology nursing community.  Please take the time to complete a short survey related to mapping dermatology nursing research activity and research development needs.

     

  • Clinical Dermatology Nursing Role Descriptors

    The BDNG has collaborated with the British Association of Dermatologists (BAD) Education Board Nursing Workstream  to develop role descriptors for dermatology nurses alongside a suggested career development guide. More information

  • The Psoriasis Association 10 year impact report published

    What a difference a decade makes! The Psoriasis Association have published their first ever 10 year impact report. Spanning from 2010 to 2020, the report explores how their work has made a difference to the lives of people affected by psoriasis over the last decade.
    Did you know that the Psoriasis Association has funded 21 PhD Studentships in the last decade and consulted on the assessment of every biologic to treat psoriasis since they began in 2004? This report explores the charity’s achievements over the past 10 years; from empowering people to make decisions regarding their psoriasis, to helping to shape NHS guidelines that affect patient care, or funding research that drives change such as making personalised medicine a reality.
    The full 10 year impact report is now available to read on the Psoriasis Association’s website.

     

  • Quality in Care Dermatology 2021

    These awards are now open for entry. The deadline for entries is 12 March 2021. More information

  • Management and Care of Patients with Vulval Conditions

    This competency document is available to BDNG members. More information

  • Dermatology Nursing Service Survey

    We undertook a snapshop survey on how dermatology nurses are delivering services during the COVID-19 crisis. Download the results

  • Emollient Guidance


    Many of our members have reported difficulties for patients obtaining emollients in primary care. The BDNG has produced  guidance on the need for emollients. Please feel free to use this document in communications with primary care.

  • NHS England Consultation

    NHS England Consultation – Items which should not routinely be prescribed in primary care: Guidance for CCGs
    Click here to view the BDNG’s response to this consultation.